The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives

Enrico Gringeri,Alessandro Furlanetto,Ilaria Billato,Matteo Cescon,Luciano De Carlis,Vincenzo Mazzaferro,Renato Romagnoli,Paolo De Simone,Marco Vivarelli,Fabrizio Di Benedetto,Matteo Ravaioli,Andrea Lauterio,Carlo Sposito,Damiano Patrono,Davide Ghinolfi,Federico Moccheggiani,Stefano Di Sandro,Francesco Enrico D’Amico,Jacopo Lanari,Martina Gambato,Silvia Trapani,Francesca Bergamo,Massimo Cardillo,Patrizia Burra,Umberto Cillo

DOI: https://doi.org/10.1007/s13304-024-01889-1

2024-09-01

Updates in Surgery

Abstract:Liver transplantation (LT) was considered an ineffective treatment for perihilar cholangiocarcinoma (pCCA) until the successful experience of the Mayo Clinic, proposing a protocol with strict inclusion criteria and neoadjuvant radio-chemotherapy. Since 2015, pCCA is considered an indication for LT in Italy only in the context of controlled prospective studies. We performed a survey among the 22 Italian Liver Transplant Centers to assess the results of LT for pCCA. Eight centers reported 53 cases from 1986 to 2021 (Bologna 12, Padova 10, Niguarda 10, Milano Tumori 8, Torino 5, Pisa 4, Ancona 2, Modena 2). Patients were divided according to whether they recieved neoadjuvant radio-chemotherapy (Group 1, 25 cases) or not (Group 2, 28 cases). Eleven patients were transplanted without neoadjuvant treatment after 2015. Overall survival at 1, 3 and 5 years was 83.8%, 56.6% and 50.6% in Group 1 and 72.4%, 41.4% and 35.5% in Gropu 2 (p = 0.13). Recurrence-free survival at 1, 3, and 5 years was 91.2%, 61.1% and 47.2% in Group 1 and 58.2%, 42.2%, and 36.1% in Group 2 (p = 0.16). A competing risk regression analysis showed a 5-year risk of cancer-related death of 19% for patients in Group 1 against 62.3% in Group 2, with a hazard ratio of 0.31 (95%CI [0.10–0.98], p 0.047). This survey promoted a discussion about the limitations of the Mayo protocol and set the basis for the adoption of a new nationwide protocol (LITHALICA–NCT06125769), having the same inclusion criteria but proposing standard of care chemotherapy as neoadjuvant regimen.

surgery